0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Supratherapeutic International Normalized Ratios in Warfarin-Treated Patients Who Receive a Highly Potentiating Antimicrobial Course—Reply

Catherine S. Riggs, PharmD1; Thomas Delate, PhD1,2; Nathan P. Clark, PharmD1,2
[+] Author Affiliations
1Department of Clinical Pharmacy, Kaiser Permanente, Aurora, Colorado
2Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Denver
JAMA Intern Med. 2014;174(7):1200-1201. doi:10.1001/jamainternmed.2014.1589.
Text Size: A A A
Published online

Extract

In Reply We thank Daniels and colleagues for their insight and comments regarding our original investigation.1 We agree with their interpretation that patients receiving antibiotics interfering with warfarin metabolism through cytochrome P450 (CYP) enzyme inhibition present a greater risk of excessive anticoagulation than do patients who are sick but do not receive antibiotics. An additional analysis of our data confirms an increased risk of a follow-up international normalized ratio (INR) of 5.0 or greater in the inhibition of CYP metabolism group compared with sick controls (8.6% vs 2.6%, respectively; P < .001).1 The importance of CYP metabolism interactions with warfarin is further underscored in the original analysis of excessive anticoagulation risk across antibiotic mechanism groups. The risk of a follow-up INR of 5.0 or greater was significantly higher in the inhibition of CYP metabolism group compared with the vitamin K disruption group (8.6% vs 3.1%, respectively; P < .017) and between the CYP metabolism group and the no interaction reported group (8.6% vs 2.1%, respectively; P < .017).1 With respect to other highly potentiating antimicrobials, miconazole and voriconazole are rarely used at our institution, and no patients prescribed these medications met study inclusion criteria.1 We did capture information on fluconazole use during our original data collection. Fluconazole administration was documented in 48 patients, with 12.5% of these patients experiencing a follow-up INR of 5.0 or greater. These results are consistent with the other medications included in the inhibition of CYP metabolism group as given in the Table. Including fluconazole in the analysis of antimicrobials inhibiting CYP metabolism increased the proportion of patients experiencing a follow-up INR of 5.0 or greater to 9.6% in this group. Despite the importance of CYP inhibition interactions relative to the other antibiotic and control groups, it is important to note that the mean INR change that we identified remained small, with only about 1 in 10 patients prescribed these agents having a follow-up INR of 5.0 or greater.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

July 1, 2014
Lisa M. Daniels, MD; Jason N. Barreto, PharmD; Pritish K. Tosh, MD
1Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota
2Department of Pharmacy Services, Mayo Clinic, Rochester, Minnesota
3Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota
JAMA Intern Med. 2014;174(7):1200. doi:10.1001/jamainternmed.2014.1615.
CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Jobs
brightcove.createExperiences();